These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 30726693)

  • 21. Nonclinical Pharmacokinetics and Absorption, Distribution, Metabolism, and Excretion of Givosiran, the First Approved
    Li J; Liu J; Zhang X; Clausen V; Tran C; Arciprete M; Wang Q; Rocca C; Guan LH; Zhang G; Najarian D; Xu Y; Smith P; Wu JT; Chong S
    Drug Metab Dispos; 2021 Jul; 49(7):572-580. PubMed ID: 33941543
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Spotlight on Givosiran as a Treatment Option for Adults with Acute Hepatic Porphyria: Design, Development, and Place in Therapy.
    Majeed CN; Ma CD; Xiao T; Rudnick S; Bonkovsky HL
    Drug Des Devel Ther; 2022; 16():1827-1845. PubMed ID: 35734365
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost savings with hemin versus givosiran for the treatment of patients with acute intermittent porphyria (AIP).
    Massachi S; Epstein J; Hurd J; Bonkovsky HL
    J Med Econ; 2020 Dec; 23(12):1441-1449. PubMed ID: 33043761
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 5-Aminolevulinate dehydratase porphyria: Update on hepatic 5-aminolevulinic acid synthase induction and long-term response to hemin.
    Lahiji AP; Anderson KE; Chan A; Simon A; Desnick RJ; Ramanujam VMS
    Mol Genet Metab; 2020 Dec; 131(4):418-423. PubMed ID: 33199206
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A randomized, placebo-controlled study of givosiran in patients with acute hepatic porphyrias (ENVISION): Final (36-month) analysis of the Taiwan Cohort.
    Lee MJ; Kuo HC; Chou LN; Sweetser MT; Wang JD
    J Formos Med Assoc; 2024 Jun; 123(6):679-686. PubMed ID: 38044204
    [TBL] [Abstract][Full Text] [Related]  

  • 26. RNA interference therapy in acute hepatic porphyrias.
    Yasuda M; Keel S; Balwani M
    Blood; 2023 Nov; 142(19):1589-1599. PubMed ID: 37027823
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel treatment options for acute hepatic porphyrias.
    Wang B
    Curr Opin Gastroenterol; 2021 May; 37(3):194-199. PubMed ID: 33769375
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dysregulation of homocysteine homeostasis in acute intermittent porphyria patients receiving heme arginate or givosiran.
    To-Figueras J; Wijngaard R; García-Villoria J; Aarsand AK; Aguilera P; Deulofeu R; Brunet M; Gómez-Gómez À; Pozo OJ; Sandberg S
    J Inherit Metab Dis; 2021 Jul; 44(4):961-971. PubMed ID: 33861472
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recovery of chronic motor neuropathy due to acute intermittent porphyria after givosiran treatment in a young boy: a case report.
    Mazzoli M; Ricci A; Vaudano AE; Marcacci M; Marchini S; Bergonzini P; Di Pierro E; Pischik E; Iughetti L; Pietrangelo A; Meletti S; Ventura P
    Eur Rev Med Pharmacol Sci; 2024 Apr; 28(8):3268-3274. PubMed ID: 38708485
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Highly Durable RNAi Therapeutic Inhibitor of PCSK9.
    Fitzgerald K; White S; Borodovsky A; Bettencourt BR; Strahs A; Clausen V; Wijngaard P; Horton JD; Taubel J; Brooks A; Fernando C; Kauffman RS; Kallend D; Vaishnaw A; Simon A
    N Engl J Med; 2017 Jan; 376(1):41-51. PubMed ID: 27959715
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [New therapeutic option for acute hepatic porphyrias].
    Stölzel U; Schuppan D
    Dtsch Med Wochenschr; 2021 Aug; 146(15):955-958. PubMed ID: 34344029
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Givosiran - Running RNA Interference to Fight Porphyria Attacks.
    Gonzalez-Aseguinolaza G
    N Engl J Med; 2020 Jun; 382(24):2366-2367. PubMed ID: 32521139
    [No Abstract]   [Full Text] [Related]  

  • 33. Case Report: Lack of Response to Givosiran in a Case of ALAD Porphyria.
    Graff E; Anderson KE; Levy C
    Front Genet; 2022; 13():867856. PubMed ID: 35991568
    [No Abstract]   [Full Text] [Related]  

  • 34. Pharmacokinetic-pharmacodynamic model of urinary δ-aminolevulinic acid reduction after givosiran treatment in patients with acute hepatic porphyria.
    Lee J; Melch M; Robbie GJ
    CPT Pharmacometrics Syst Pharmacol; 2023 Jun; 12(6):842-852. PubMed ID: 36883675
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ALAS1 gene expression is down-regulated by Akt-mediated phosphorylation and nuclear exclusion of FOXO1 by vanadate in diabetic mice.
    Oliveri LM; Davio C; Batlle AM; Gerez EN
    Biochem J; 2012 Mar; 442(2):303-10. PubMed ID: 22070747
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preventing hyperhomocysteinemia using vitamin B
    Redonnet-Vernhet I; Mercié P; Lebreton L; Blouin JM; Bronnimann D; Mesli S; Guibet C; Ribeiro E; Gensous N; Duffau P; Gouya L; Richard E
    Mol Genet Metab Rep; 2024 Jun; 39():101076. PubMed ID: 38601120
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Givosiran for Acute Intermittent Porphyria.
    Gomá-Garcés E; Pérez-Gómez MV; Ortíz A
    N Engl J Med; 2020 Nov; 383(20):1989. PubMed ID: 33176091
    [No Abstract]   [Full Text] [Related]  

  • 38. Plasma porphobilinogen as a sensitive biomarker to monitor the clinical and therapeutic course of acute intermittent porphyria attacks.
    Sardh E; Harper P; Andersson DE; Floderus Y
    Eur J Intern Med; 2009 Mar; 20(2):201-7. PubMed ID: 19327613
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hepatocyte transplantation ameliorates the metabolic abnormality in a mouse model of acute intermittent porphyria.
    Yin Z; Wahlin S; Ellis EC; Harper P; Ericzon BG; Nowak G
    Cell Transplant; 2014; 23(9):1153-62. PubMed ID: 23582197
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recurrent attacks of acute hepatic porphyria: major role of the chronic inflammatory response in the liver.
    Schmitt C; Lenglet H; Yu A; Delaby C; Benecke A; Lefebvre T; Letteron P; Paradis V; Wahlin S; Sandberg S; Harper P; Sardh E; Sandvik AK; Hov JR; Aarsand AK; Chiche L; Bazille C; Scoazec JY; To-Figueras J; Carrascal M; Abian J; Mirmiran A; Karim Z; Deybach JC; Puy H; Peoc'h K; Manceau H; Gouya L
    J Intern Med; 2018 Jul; 284(1):78-91. PubMed ID: 29498764
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.